Immunogenicity, safety, and reactogenicity of a half- versus full-dose BNT162b2 (Pfizer-BioNTech) booster following a two-dose ChAdOx1 nCoV-19, BBIBP-CorV, or Gam-COVID-Vac priming schedule in Mongolia: a randomised, controlled, non-inferiority trial
在蒙古,一项随机、对照、非劣效性试验评估了接种两剂 ChAdOx1 nCoV-19、BBIBP-CorV 或 Gam-COVID-Vac 疫苗后,接种半剂量与全剂量 BNT162b2(辉瑞-BioNTech)加强针的免疫原性、安全性和反应原性。
期刊:The Lancet Regional Health Western Pacific
影响因子:8.1
doi:10.1016/j.lanwpc.2023.100953
Batmunkh, Tsetsegsaikhan; Moore, Kerryn A; Thomson, Helen; Altangerel, Bolor; Amraa, Otgonjargal; Avaa, Naranbaatar; Batbayar, Lkhagvagaram; Batsukh, Khishigjargal; Bright, Kathryn; Burentogtokh, Tsogjargal; Ha Do, Lien Anh; Dorj, Gantuya; Hart, John D; Javkhlantugs, Khulan; Jigjidsuren, Sarantsetseg; Justice, Frances; Li, Shuo; Licciardi, Paul V; Mashbaatar, Khaliunaa; Mazarakis, Nadia; Neal, Eleanor F G; Nguyen, Cattram Duong; Ochirbat, Batbayar; Tsolmon, Bilegtsaikhan; Tuya, Alimaa; Surenjav, Unursaikhan; von Mollendorf, Claire; Mulholland, Kim